Back

Triglycerides and cardiovascular risk: the importance of treating hypertriglyceridaemia

Event: ESC CONGRESS 2014
Topic: Primary cardiovascular prevention: interventions and outcomes
Session type: EBAC Accredited Educational Programme
Organised by University Hospital, Umea / Course Director: Ulf Naeslund / Supported by an unrestricted educational grant from AstraZeneca
Date: 2 September 2014
Time: 12:45 - 13:45

0
5 presentations in this session

Welcome and introduction - Triglycerides and cardiovascular risk.

Speaker: Professor J. Chapman (Paris, FR)
Access
Slides
0
Thumbnail

The genetic basis of hypertriglyceridaemic states.

Speaker: Professor E. Stroes (Amsterdam, NL)
Access
Slides
0
Thumbnail

Pathophysiology of hypertriglyceridaemia: relationship with cardiovascular risk.

Speaker: Professor B. Nordestgaard (Copenhagen, DK)
Access
Slides
0
Thumbnail

Therapeutic options for hypertriglyceridaemia: the future.

Speaker: Professor J. Chapman (Paris, FR)
Access
Slides
0
Thumbnail

Discussion and closing remarks - Triglycerides and cardiovascular risk.

Speaker: Professor J. Chapman (Paris, FR)
Access
0
Thumbnail

5 speakers from this session

Professor John Chapman

Sorbonne University, Paris (France)
15 presentations
0 follower

Professor Erik Stroes

Academic Medical Center of Amsterdam, Amsterdam (Netherlands (The))
18 presentations
0 follower

Professor Borge Nordestgaard

Copenhagen University Hospital - Herlev Gentofte, Copenhagen (Denmark)
8 presentations
1 follower

Professor John Chapman

Sorbonne University, Paris (France)
15 presentations
0 follower

Professor John Chapman

Sorbonne University, Paris (France)
15 presentations
0 follower

This platform is supported by

logo Novo Nordisk